BDNF and Alzheimer disease: An open label phase1 clinical trial based on Adeno-Associated Virus (AAV)-Based, Vector-Mediated Delivery of Human Brain Derived Neurotrophic Factor (AAV2-BDNF) in subjects with early AD and MCI has been started by the Tuszynski group last year.